Tuesday, 17 November 2026Peptide medicines at the counter: price, coverage, supply, rules.

Reading as
What is this?
CoverageUK

GLP 1 aftercare gap is a commissioning choice says nutrition scientist

Dr Federica Amati says health systems fund GLP 1 drugs but have not built the care that follows when patients stop and weight tends to return. She put NHS capacity at about 220,000 places over three years for 3.4 million eligible people.

Editorial illustration for the story: GLP 1 aftercare gap is a commissioning choice says nutrition scientist
Illustration: Peptide Town. Cut-paper collage, not data.

Who feels it

  • Payers Rethink

    Amati calls the missing aftercare a commissioning decision and says systems must fund the maintenance phase, not only first weight loss.

  • Patients Adjust

    Weight tends to return after stopping, and the NHS has no set support route for people coming off treatment, so ask early what follow up exists.

  • Prescribers Adjust

    Amati urges eating disorder screening, function checks such as grip strength and walking speed, and a structured review at three to six months.

  • Pharmacies Worth knowing

    No new service or rule yet, but any funded maintenance pathway could add follow up and review work around GLP 1 supply.

  • Sellers Worth knowing

    Private prescribing is lower in deprived areas where obesity is most common; the talk sets no new rule for private providers.

Health systems fund GLP 1 weight loss drugs but have not built the care that follows when patients stop, a UK nutrition scientist told a European health conference on 3 November 2026. Dr Federica Amati, head nutritionist at ZOE, said GLP 1 aftercare is largely missing from obesity services and called its absence a funding choice. She put planned NHS capacity at about 220,000 treatment places over three years against an estimated 3.4 million eligible people, and warned the gap could deepen health inequalities in England.

Weight regain after stopping GLP 1 treatment

Amati spoke at The Economist's Future of Health Europe event in a session on what GLP 1 drugs reveal about metabolic health, according to a report by the European Medical Journal. Her starting point was that semaglutide and tirzepatide clearly work for weight loss. Her concern was the period after treatment ends. Citing an analysis that pooled 37 studies, she said people regained weight at an average of about 0.4 kg a month after stopping. Markers of heart and metabolic health, she said, were projected to drift back toward where they began within about 1.4 years. For anyone watching costs, weight regain after stopping GLP 1 drugs matters because a payer that funds a course and then ends it may lose much of the health gain it paid for.

Amati also stressed that the average hides a wide spread. Some people regain weight quickly and others slowly, so she argued against assuming every patient will follow the same curve. That spread, in her view, is the case for individual follow up, yet she said health services have mostly not built structured GLP 1 aftercare routes for people coming off treatment. She described the lack of support after treatment as one of the largest gaps in obesity care and urged more spending on maintenance rather than on first weight loss alone. Her talk, as reported, did not set out what a maintenance pathway would cost, who would deliver it or how many NHS patients have already stopped treatment.

Figure Amati citedWhat it describes
37 studiesPooled analysis of weight regain after treatment stops
About 0.4 kg a monthAverage regain after stopping
About 1.4 yearsProjected time for heart and metabolic markers to return toward baseline
20 trials with 15,782 peoplePooled analysis of body composition on treatment
35.2% and 25.4%Share of weight lost as lean mass on semaglutide and on tirzepatide
17.5%Share of weight lost as lean mass with lifestyle programmes that included resistance training
37.4% and 19.8%Obesity prevalence in the most and least deprived communities in England
About 220,000 and 3.4 millionNHS treatment places planned over three years and estimated eligible people

NHS weight loss jabs and the private route

The access argument is where the talk meets this site's beat. Amati cited obesity prevalence of 37.4% in the most deprived communities in England, against 19.8% in the least deprived. Yet private prescribing, she said, was lower among more disadvantaged groups, so the people most likely to need treatment are the least likely to pay for it themselves. Access to NHS weight loss jabs is meant to close that gap, but she put planned capacity at about 220,000 treatment places over three years. Set against an estimated 3.4 million eligible people, that is roughly one place for every 15 who qualify. A Commons committee made a similar point in October, when MPs called the rollout unambitious and warned of a two tier system.

Set against an estimated 3.4 million eligible people, that is roughly one place for every 15 who qualify.

Amati warned that the imbalance could widen existing inequalities, especially if patients receive the drug without nutrition, psychological and long term clinical support alongside it. That warning ties access directly to GLP 1 aftercare, because a place on a programme is only part of the offer if follow up is thin. The pattern is not limited to England. A BBC freedom of information survey covered here in October found just 705 people in Scotland treated for weight loss on the NHS, all through small pilots. Amati's figures, as reported, do not show what share of NHS patients move to a private prescription after leaving a programme, or how many simply go without. Those numbers would show whether the gap she describes is growing or shrinking.

Lean mass loss and the missing function tests

Amati also questioned whether trials measure the outcomes patients care about most. She presented a pooled analysis of 20 randomised trials with 15,782 participants. In that work, lean mass made up about 35.2% of the weight lost on semaglutide and 25.4% on tirzepatide, compared with 17.5% for lifestyle programmes that included resistance training. She was careful about what those numbers show. Lean mass is not the same as muscle, she said, because the measure also picks up changes in body water and other tissue, so a drop in lean mass does not prove a loss of strength. The comparison also sets drug treatment against programmes with exercise built in, so it is not a direct head to head test of the drugs.

The more striking finding, in her account, was what the trials left out. None of the 20 trials in the pooled analysis measured physical function at all. Amati called for routine checks such as grip strength, walking speed and chair stand tests, along with enough protein and resistance training while patients are on treatment. For payers, the lean mass loss question is also a budget question. Function testing, dietitian time and supervised exercise all cost money, and none of them comes bundled with a prescription. If those services are expected but not funded, the work falls on primary care teams or on patients who can afford private help, which is the same split that her access figures already show in England.

What funded GLP 1 aftercare would need

Amati listed several priorities for obesity services. They included screening for eating disorders, nutrition and psychological support, routine checks of physical function, and a structured review of how each patient is responding after three to six months. She also argued that medicine alone cannot fix the food environment behind poor metabolic health, and closed by asking whether health systems are "treating biology while leaving the environment intact." Her core message for health leaders was that the medicines are effective while the service built around them is still missing, a gap she called "a commissioning decision rather than a scientific one." In other words, she placed the problem in obesity care commissioning and with the people who set budgets, not with the scientists who run trials.

What is not known matters as much as what was said. These were views given in a conference talk, not a new NHS policy, a NICE recommendation or a change to any coverage rule, and the EMJ report includes no response from NHS England or any other funder. The talk gave no cost for a maintenance pathway and no date for any change. Other systems have tried to answer the stopping question with rules rather than services. Cyprus, for example, now pays for Mounjaro only with weight loss targets and a two year limit on cover. For patients, a practical step is to ask a prescriber early what support exists once treatment ends. This story is research framing only and is not medical advice.

Conclusion

Amati's case is simple to state and hard to fund. The drugs she discussed produce real weight loss, yet the average patient regains weight after stopping, and the services that might slow that regain are rarely paid for. Until commissioners decide who funds GLP 1 aftercare, access will often mean a prescription with little behind it, and the shortfall will fall hardest on people who cannot pay privately. Readers should watch for any NHS or NICE move on maintenance care.

Source Dr Federica Amati of ZOE speaking at The Economist's Future of Health Europe event on 3 November 2026, as reported by the European Medical Journal (EMJ) on 4 November 2026

Spotted an error? Tell us through the contact form; we follow the corrections policy.